Several Companies Highlight Upcoming Presentations At American Society Of Clinical Oncology Meeting Jun. 3-7: Provectus, Advaxis, Adicet Bio, Cullinan Oncology, Galera, BeiGene, Arcellx, PDS Biotech, Tempest, Karyopharm

4/27/22 10:02:45 AM ET

$ACET

$ACLX

$ADXS

$BGNE

Biotechnology: Pharmaceutical Preparations

Health Care

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $ACET alert in real time by email

Several Companies Highlight Upcoming Presentations At American Society Of Clinical Oncology Meeting Jun. 3-7: Provectus, Advaxis, Adicet Bio, Cullinan Oncology, Galera, BeiGene, Arcellx, PDS Biotech, Tempest, Karyopharm

Get the next $ACET alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ACET
$ACLX
$ADXS
$BGNE

Company	Date	Price Target	Rating	Analyst
Cullinan Therapeutics Inc. $CGEM	10/24/2024	$30.00	Buy	UBS
Arcellx Inc. $ACLX	10/8/2024	$109.00	Buy	Redburn Atlantic
Adicet Bio Inc. $ACET	9/30/2024	$7.00	Buy	Guggenheim
BeiGene Ltd. $BGNE	9/18/2024	$288.00	Mkt Outperform	JMP Securities
Adicet Bio Inc. $ACET	9/11/2024		Buy → Neutral	H.C. Wainwright
Arcellx Inc. $ACLX	9/3/2024		Overweight	Cantor Fitzgerald
Arcellx Inc. $ACLX	5/31/2024	$70.00	Overweight	Piper Sandler
Cullinan Therapeutics Inc. $CGEM	5/1/2024	$40.00	Buy	Stifel

More analyst ratings

Labcorp CFO Glenn Eisenberg Announces Plans to Retire
Julia Wang Named Chief Financial Officer Beginning December 2, 2024 BURLINGTON, N.C., Nov. 19, 2024 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, announced today that Executive Vice President and Chief Financial Officer (CFO) Glenn Eisenberg will retire from the company and Julia Wang will join on December 2, 2024, as Executive Vice President and Chief Financial Officer. Mr. Eisenberg will remain at Labcorp as Special Advisor to the CEO through April 2025 to ensure a seamless transition of his current role and assist with strategic initiatives underway within the company.
11/19/24 7:00:00 AM ET
$BGNE
$LH
Biotechnology: Pharmaceutical Preparations
Health Care
Medical Specialities
BeiGene Announces Settlement of Litigation Against Generic Filer of BRUKINSA
Agreement provides for generic entry of innovative BTK inhibitor in 2037 BeiGene, Ltd. (NASDAQ:BGNE, HKEX: 06160, SSE: 688235)), a global oncology company which intends to change its name to BeOne Medicines Ltd., today announced it has entered into a settlement agreement with MSN Pharmaceuticals, Inc. and MSN Laboratories Private Ltd. resolving patent litigation related to MSN's Abbreviated New Drug Application (ANDA) seeking approval to market a generic version of BRUKINSA® (zanubrutinib) in the U.S. Under the terms of the agreement, MSN will not be able to sell a generic version of BRUKINSA earlier than June 15, 2037, subject to potential acceleration or extension under certain custom
11/19/24 6:00:00 AM ET
$BGNE
Biotechnology: Pharmaceutical Preparations
Health Care
Adicet Opens Enrollment for ADI-270 Phase 1 Clinical Trial in Metastatic/Advanced Clear Cell Renal Cell Carcinoma
First gamma delta CAR T cell therapy with the potential to address solid tumors entering clinical trials Preliminary Phase 1 clinical data expected in the first half of 2025 Adicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the opening of enrollment for the Phase 1 clinical trial evaluating ADI-270 in patients with metastatic/advanced clear cell renal cell carcinoma (ccRCC). "Solid tumors represent one of the highest unmet medical needs in oncology and have yet to benefit from the breakthroughs observed with CAR T cell therapies in hematologic mal
11/18/24 4:00:00 PM ET
$ACET
Biotechnology: Pharmaceutical Preparations
Health Care

$ACET
$ACLX
$ADXS
$BGNE
Financials

Live finance-specific insights

Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
Global Phase 1 study of CLN-978 in systemic lupus erythematosus (SLE) cleared to initiate in U.S. and Australia; initial clinical data expected in Q4 2025 CLN-619 on-track for initial expansion cohort data in endometrial and cervical cancers in Q2 2025 Zipalertinib pivotal Phase 2b study enrollment completed ahead of schedule; results expected mid-year 2025 CAMBRIDGE, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (NASDAQ:CGEM, "Cullinan")), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today reported recent and anticipated business highlights and announced its financial results for the third quarter ended September 30, 202
11/7/24 7:00:00 AM ET
$CGEM
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results
Investigational New Drug (IND) application for CLN-978 in systemic lupus erythematosus (SLE) remains on track to be filed in third quarter of 2024 Company to pursue rheumatoid arthritis (RA) as second autoimmune indication for CLN-978 development CLN-619 combination therapy data presented at ASCO demonstrated objective responses in oncogenic driver mutation NSCLC, which is typically unresponsive to checkpoint inhibition Company appoints Mary Thistle to its Board of Directors CAMBRIDGE, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (NASDAQ:CGEM, "Cullinan"))), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today reported re
8/8/24 7:00:00 AM ET
$CGEM
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
Combination and monotherapy solid tumor dose escalation data for CLN-619 to be presented in a poster session at ASCO 2024 Annual Meeting CLN-978 development to focus exclusively on autoimmune diseases, starting with systemic lupus erythematosus (SLE) as the first indication Cash and investments of $434.8 million as of March 31, 2024, plus gross proceeds of $280 million from April private placement extends cash runway into 2028 Company appoints David Meek to its Board of Directors CAMBRIDGE, Mass., May 15, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (NASDAQ:CGEM, "Cullinan"))), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today reporte
5/15/24 4:05:00 PM ET
$CGEM
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

Labcorp CFO Glenn Eisenberg Announces Plans to Retire
Julia Wang Named Chief Financial Officer Beginning December 2, 2024 BURLINGTON, N.C., Nov. 19, 2024 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, announced today that Executive Vice President and Chief Financial Officer (CFO) Glenn Eisenberg will retire from the company and Julia Wang will join on December 2, 2024, as Executive Vice President and Chief Financial Officer. Mr. Eisenberg will remain at Labcorp as Special Advisor to the CEO through April 2025 to ensure a seamless transition of his current role and assist with strategic initiatives underway within the company.
11/19/24 7:00:00 AM ET
$BGNE
$LH
Biotechnology: Pharmaceutical Preparations
Health Care
Medical Specialities
Global Oncology Innovator BeiGene Appoints Shalini Sharp to Board of Directors
BeiGene, Ltd. (NASDAQ:BGNE, HKEX: 06160, SSE: 688235))), a global oncology company, today announced the appointment of Shalini Sharp to its Board of Directors and as a member of the Board's Audit Committee, effective September 27, 2024. "We are fortunate to welcome Shalini to the Board of Directors at this pivotal moment of growth," said John V. Oyler, Co-Founder, Chairman and CEO of BeiGene. "The Board is looking forward to collaborating with Shalini, whose extensive experience in leading innovative global pharmaceutical companies will be invaluable as we enter new markets, advance our pipeline of groundbreaking cancer therapies, and embark on a transformative growth phase. Her financial
9/26/24 6:00:00 AM ET
$BGNE
Biotechnology: Pharmaceutical Preparations
Health Care
BeiGene Announces Updates to Commercial Leadership Team
BeiGene, Ltd. (NASDAQ:BGNE, HKEX: 06160, SSE: 688235))), a global oncology company, today announced the appointment of Matt Shaulis as General Manager of North America, effective September 25. "We are excited to welcome Matt, who brings a wealth of global pharmaceutical experience, including leading the commercialization of blockbuster franchises at multiple multinational companies," said John V. Oyler, Co-Founder, Chairman and CEO at BeiGene. "Matt's management will be pivotal as we continue our leadership in hematology with BRUKINSA and replicate that success in solid tumors, with a deep and exciting pipeline of innovative therapies." Mr. Shaulis is a global commercial executive with ov
9/9/24 7:00:00 AM ET
$BGNE
Biotechnology: Pharmaceutical Preparations
Health Care

Several Companies Highlight Upcoming Presentations At American Society Of Clinical Oncology Meeting Jun. 3-7: Provectus, Advaxis, Adicet Bio, Cullinan Oncology, Galera, BeiGene, Arcellx, PDS Biotech, Tempest, Karyopharm

Chat with this insight

Recent Analyst Ratings for $ACET$ACLX$ADXS$BGNE

$ACET$ACLX$ADXS$BGNE Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

UBS initiated coverage on Cullinan Therapeutics with a new price target

Redburn Atlantic initiated coverage on Arcellx with a new price target

Guggenheim resumed coverage on Adicet Bio with a new price target

$ACET$ACLX$ADXS$BGNE Press Releases

Fastest customizable press release news feed in the world

Labcorp CFO Glenn Eisenberg Announces Plans to Retire

BeiGene Announces Settlement of Litigation Against Generic Filer of BRUKINSA

Adicet Opens Enrollment for ADI-270 Phase 1 Clinical Trial in Metastatic/Advanced Clear Cell Renal Cell Carcinoma

$ACET$ACLX$ADXS$BGNE Financials

Live finance-specific insights

Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results

Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results

Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results

$ACET$ACLX$ADXS$BGNE Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G filed by Arcellx Inc.

Amendment: SEC Form SC 13G/A filed by Adicet Bio Inc.

Amendment: SEC Form SC 13G/A filed by Cullinan Therapeutics Inc.

$ACET$ACLX$ADXS$BGNE Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

$ACET$ACLX$ADXS$BGNE Leadership Updates

Live Leadership Updates

$ACET$ACLX$ADXS$BGNE Market Insights

Live Market Insights

$ACET$ACLX$ADXS$BGNE Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Schneid Yair bought $590,424 worth of shares (2,780,407 units at $0.21), increasing direct ownership by 35% to 10,823,610 units (SEC Form 4) (Amendment)

Schneid Yair bought $166,417 worth of shares (932,402 units at $0.18), increasing direct ownership by 13% to 8,043,203 units (SEC Form 4)

Orbimed Advisors Llc bought $7,500,000 worth of shares (3,125,000 units at $2.40) (SEC Form 4)

Labcorp CFO Glenn Eisenberg Announces Plans to Retire

Global Oncology Innovator BeiGene Appoints Shalini Sharp to Board of Directors

BeiGene Announces Updates to Commercial Leadership Team

BeiGene Opens U.S. Biologics Manufacturing And Clinical R&D Facility In New Jersey With $800M Investment

Decoding 8 Analyst Evaluations For Arcellx

Canaccord Genuity Maintains Buy on Arcellx, Maintains $85 Price Target

CHIEF FINANCIAL OFFICER Gilson Michelle sold $156,508 worth of shares (1,761 units at $88.87) and exercised 3,000 shares at a strike of $8.66, increasing direct ownership by 70% to 3,000 units (SEC Form 4)

Director Patel Kavita exercised 1,500 shares at a strike of $6.66 and sold $159,495 worth of shares (1,500 units at $106.33) (SEC Form 4)

CHIEF FINANCIAL OFFICER Gilson Michelle exercised 7,200 shares at a strike of $8.66 and sold $1,242,170 worth of shares (12,354 units at $100.55), decreasing direct ownership by 75% to 1,761 units (SEC Form 4)

$ACET$ACLX$ADXS$BGNE SEC Filings

BeiGene Ltd. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

Adicet Bio Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

SEC Form NT 10-Q filed by Galera Therapeutics Inc.

Recent Analyst Ratings for
$ACET
$ACLX
$ADXS
$BGNE

$ACET
$ACLX
$ADXS
$BGNE
Analyst Ratings

$ACET
$ACLX
$ADXS
$BGNE
Press Releases

$ACET
$ACLX
$ADXS
$BGNE
Financials

$ACET
$ACLX
$ADXS
$BGNE
Large Ownership Changes

$ACET
$ACLX
$ADXS
$BGNE
Insider Purchases

$ACET
$ACLX
$ADXS
$BGNE
Leadership Updates

$ACET
$ACLX
$ADXS
$BGNE
Market Insights

$ACET
$ACLX
$ADXS
$BGNE
Insider Trading

$ACET
$ACLX
$ADXS
$BGNE
SEC Filings